Hologic, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000C3NTN5
HOLX
Hologic, Inc.
GICS: 35101010
·
Sektor: Healthcare
·
Sub-Sektor: Medical Instruments & Supplies
NAME
Hologic, Inc.
ISIN
US4364401012
TICKER
HOLX
MIC
XNAS
REUTERS
HOLX.OQ
BLOOMBERG
HOLX US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Di., 25.02.2025
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Raymond James & Associates' 46th Annual Institutional Investors Conference on Tuesday, March 4 at 11 a.m. Eastern Time (ET).
The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investor...
Do., 20.02.2025
Hologic
US4364401012
Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm® Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate biopsy procedures,1-2 is now CE-marked. The technology received clearance from the U.S. Food and Drug...
Di., 18.02.2025
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Aptima® SARS-CoV-2 assay, which was first granted Emergency Use Authorization (EUA) status in May 2020.
“Our COVID test was instrumental in addressing critical testing needs during the pandemic and offered h...
Mi., 05.02.2025
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2024.
“Our financial results for the first quarter of 2025 were consistent with our guidance overall,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Total revenue finished in li...
Di., 21.01.2025
Hologic
US4364401012
Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index, one of the largest collections of data on women’s health and well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/
Hologic, Inc. (Nasdaq: HOLX), a leading wo...
So., 12.01.2025
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024.
The Company expects to report total revenues of approximately $1,021.8 million, an increase of 0.9% compared to the prior year period, or 1.0% in constant currency.
“Our fiscal Q1 revenue finished in line with our guid...
Di., 07.01.2025
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time.
The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hol...
Mo., 06.01.2025
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2025 on Wednesday, February 5, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Interested participants may listen to the call by ...
Mo., 06.01.2025
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.
“We are excited to complete the acquisition o...
Mi., 18.12.2024
Hologic
US4364401012
Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu.
This ...
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
